Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial (Q84922572)
Jump to navigation
Jump to search
scientific article published on 01 February 2012
Language | Label | Description | Also known as |
---|---|---|---|
English | Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial |
scientific article published on 01 February 2012 |
Statements
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial (English)
W Rigby
H-P Tony
K Oelke
B Combe
A Laster
C A von Muhlen
E Fisheleva
C Martin
H Travers
1 February 2012